Skip to main content

Table 1 Molecular, functional characteristics and source of origin of the indicated cell lines

From: Evolving neoantigen profiles in colorectal cancers with DNA repair defects

Sample

Microsatellite status

Altered MSI markers

Genome evolvability

Split ratio

In vitro doubling time

Growth rate

Source

C10

Stable

–

Stable

0.34

2.33

0.30

ECACC

C106

Stable

–

Stable

0.35

2.50

0.28

ECACC

C125PM

Stable

–

Stable

0.34

2.37

0.29

ECACC

C32

Stable

–

Stable

0.18

1.54

0.45

ECACC

C70

Stable

–

Stable

0.4

2.76

0.25

ECACC

C75

Stable

–

Stable

0.36

2.46

0.28

ECACC

C99

Stable

–

NA

NA

NA

NA

ECACC

CACO2

Stable

–

Stable

0.26

1.83

0.38

ATCC

CAR1

Stable

–

Stable

0.36

2.47

0.28

JCRB

CCK81

Unstable

bat26-nr21-bat25-mono27-nr24

Evolving

0.34

2.53

0.27

RIKEN

CL14

Stable

–

NA

NA

NA

NA

DSMZ

COCM1

Stable

–

Evolving

0.3

2.34

0.30

JCRB

COGA1

Unstable

bat26-mono27-nr24

NA

NA

NA

NA

Dr. Hubera

COGA2

Stable

–

Stable

0.32

2.22

0.31

Dr. Hubera

COGA5

Stable

–

Stable

0.20

1.69

0.41

Dr. Hubera

COGA8

Stable

–

Stable

0.22

1.67

0.41

Dr. Hubera

COLO201

Stable

–

NA

NA

NA

NA

ATCC

COLO94H

Stable

–

Stable

0.45

2.81

0.25

CLS

DIFI

Stable

–

NA

NA

NA

NA

Dr. Baselgab

DLD1

Unstable

bat26-nr21-bat25-mono27-nr24

Evolving

0.07

0.98

0.71

NCI60

HCA24

Stable

–

Evolving

0.33

2.22

0.31

ECACC

HCA46

Stable

–

Stable

0.4

2.41

0.29

ECACC

HCC2998

Stable

–

Stable

0.34

2.33

0.30

NCI60

HDC114

Stable

–

Evolving

0.23

1.69

0.41

DKFZc

HDC142

Stable

–

Evolving

0.35

2.42

0.29

DKFZc

HDC82

Stable

–

NA

NA

NA

NA

DKFZc

HRA16

Stable

–

NA

NA

NA

NA

ECACC

HROC24

Unstable

bat26-nr21-bat25-mono27-nr24

Evolving

0.16

1.23

0.56

Dr. Linnebacherd

HROC32

Stable

–

Stable

0.62

6.07

0.11

Dr. Linnebacherd

HROC334

Stable

–

Stable

0.45

2.83

0.24

Dr. Linnebacherd

HROC39

Stable

–

Stable

0.5

3.92

0.18

Dr. Linnebacherd

HROC69

Stable

–

Stable

0.33

2.26

0.31

Dr. Linnebacherd

HT115

Stable

–

Evolving

0.24

1.78

0.39

ECACC

HT29

Stable

–

Stable

0.16

1.38

0.50

NCI60

HT55

Stable

–

Stable

0.33

2.21

0.31

ECACC

LIM1215

Unstable

bat26-nr21-bat25-mono27-nr24

Evolving

0.15

1.24

0.56

Dr. Whiteheade

LIM2099

Stable

–

Stable

0.33

2.26

0.31

Dr. Whiteheade

LOVO

Unstable

nr21-bat25-mono27-nr24

NA

NA

NA

NA

ATCC

LS180

Unstable

bat26-nr21-bat25-mono27-nr24

Evolving

0.25

1.90

0.37

ATCC

LS411N

Unstable

bat26-nr21-bat25-mono27-nr24

Evolving

0.32

2.29

0.30

ATCC

MDST8

Stable

–

Stable

0.15

1.31

0.53

ECACC

NCIH716

Stable

–

NA

NA

NA

NA

ATCC

OUMS23

Stable

–

Stable

0.26

1.70

0.41

JCRB

OXCO3

Stable

–

Stable

0.23

1.76

0.39

Dr. Cerundolof

RW7213

Stable

–

Stable

0.4

2.60

0.27

Dr. Arangog

SNU1040

Unstable

bat26-nr21-bat25-mono27-nr24

Evolving

0.54

4.14

0.17

KCLB

SNU1181

Stable

–

Stable

0.62

4.65

0.15

KCLB

SNU1235

Stable

–

Evolving

0.35

2.33

0.30

KCLB

SNU1411

Stable

–

Evolving

0.44

2.76

0.25

KCLB

SNU1460

Stable

–

NA

NA

NA

NA

KCLB

SNU1684

Unstable

bat26-nr21-bat25-mono27-nr24

NA

NA

NA

NA

KCLB

SNU175

Unstable

bat26-nr21-bat25-mono27

NA

NA

NA

NA

KCLB

SNU283

Stable

–

NA

NA

NA

NA

KCLB

SNU479

Stable

–

NA

NA

NA

NA

KCLB

SNU81

Stable

–

Evolving

0.42

2.33

0.30

KCLB

SNU977

Stable

–

Stable

0.42

2.71

0.26

KCLB

SNUC1

Stable

–

NA

NA

NA

NA

KCLB

SW1417

Stable

–

NA

NA

NA

NA

ATCC

SW1463

Stable

–

NA

NA

NA

NA

ATCC

SW480

Stable

–

Stable

0.18

1.64

0.42

ATCC

SW837

Stable

–

Stable

0.27

2.07

0.34

ATCC

V411

Stable

–

Stable

0.22

1.91

0.36

Dr. Markovitzh

V481

Unstable

bat26-nr21-bat25-mono27-nr24

NA

NA

NA

NA

Dr. Markovitzh

WIDR

Stable

–

NA

NA

NA

NA

Dr. Bernardsi

  1. Non-commercial cell lines were provided by (a) Dr. L. A. Huber, Cell Biology/Biocenter, Medical University of Innsbruck, Innsbruck, Austria; (b) Dr. Baselga, Chairman & Professor of Medicine, Vall d’Hebron Institute of Oncology (V.H.I.O.), Vall d’ Hebron University Hospital, Barcelona, Spain; (c) Dr. M. Schawb, Division of Tumour Genetics - B030 German Cancer Research Center (DKFZ), Heidelberg, Germany; (d) Dr. M. Linnebacher, Division of Molecular Oncology and Immunotherapy, Department of General Surgery, University of Rostock, Rostock, Germany; (e) Dr. R.H. Whitehead, Depts of Medicine, Cell and Developmental Biology and Cancer Biology, Vanderbilt University, Nashville, USA; (f) Dr. V. Cerundolo, Nuffield Dept of Clinical Medicine, John Radcliffe Hospital, Oxford, UK; (g) Dr. D. Arango, Group of Molecular Oncology, Nanomedicine Research Program, Molecular Biology and Biochemistry Research Center, CIBBIM Nanomedicine, Vall d’Hebron, Barcelona, Spain; (h) Dr. S. Markovitz, Case Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, Case Western Reserve University, Cleveland, USA; (i) Dr. R. Bernards, Division of Molecular Carcinogenesis B7, Netherlands Cancer Institute, Amsterdam, The Netherlands.